Results 71 to 80 of about 1,110,077 (212)

Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial [PDF]

open access: yes, 2009
<br>Background: Metformin reduces cardiovascular risk in patients with type 2 diabetes seemingly independent of lowering blood glucose concentration. We assessed the cardiovascular effects of metformin in individuals without type 2 diabetes.</br&
Eddy   +33 more
core   +5 more sources

Intravenous meloxicam for the treatment of moderate to severe acute pain: a pooled analysis of safety and opioid-reducing effects. [PDF]

open access: yes, 2019
BACKGROUND AND OBJECTIVES: To describe the safety and tolerability of intravenous meloxicam compared with placebo across all phase II/III clinical trials.
Bergese, Sergio   +7 more
core   +1 more source

Ketamine Usage Effectivity on Treatment-Resistant Depression Diagnosed Patients: a Scoping Review

open access: yesJurnal Psikiatri Surabaya
Introductions: In Indonesia, a median of 6.1% of people diagnosed with depression disorder are people over 15 years old. Only 9% of that amount underwent medical treatment, while the rest, 91%, did not undergo treatment for their depressive conditions ...
Satrio Wahyu Nugroho   +3 more
doaj   +1 more source

One Year Follow-up of a Randomized, Double-Blind, Placebo-Controlled Trial of Percutaneous Peripheral Nerve Stimulation for Chronic Neuropathic Pain Following Amputation [PDF]

open access: yes, 2019
INTRODUCTION Over 85% of patients experience residual limb (RLP) and/or phantom limb (PLP) pain following amputation. Peripheral nerve stimulation (PNS) is a non-opioid approach to relieve postamputation neuropathic pain.
Boggs, Josh W   +12 more
core  

Levosimendan for the prevention of acute organ dysfunction in sepsis [PDF]

open access: yes, 2016
BACKGROUND Levosimendan is a calcium-sensitizing drug with inotropic and other properties that may improve outcomes in patients with sepsis. METHODS We conducted a double-blind, randomized clinical trial to investigate whether levosimendan reduces the ...
Al-Beidh, F   +16 more
core   +2 more sources

Sotatercept safety and effects on hemoglobin, bone, and vascular calcification [PDF]

open access: yes, 2019
Introduction: Patients with end-stage kidney disease (ESKD) exhibit anemia, chronic kidney disease‒mineral bone disorder (CKD-MBD), and cardiovascular disease.
Connarn, Jamie N   +8 more
core   +1 more source

Chlorpromazine versus placebo for schizophrenia [PDF]

open access: yes, 2014
BackgroundChlorpromazine, formulated in the 1950s, remains a benchmark treatment for people with schizophrenia.ObjectivesTo review the effects of chlorpromazine compared with placebo, for the treatment of schizophrenia.Search methodsWe searched the ...
Abrams   +486 more
core   +1 more source

Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial

open access: yesEfficacy and Mechanism Evaluation, 2015
Background: Diarrhoea-predominant irritable bowel syndrome (IBS-D) is a common outcome after inflammation due to bacterial gastroenteritis. Several studies have shown ongoing immune activation in the mucosa of patients with IBS-D and a number of studies ...
Ching Lam   +12 more
doaj   +1 more source

Aged garlic extract reduces low attenuation plaque in coronary arteries of patients with diabetes: A randomized, double-blind, placebo-controlled study. [PDF]

open access: yes, 2020
Several previous studies have demonstrated that aged garlic extract (AGE) inhibits the progression of coronary artery calcification and non-calcified plaque (NCP) in the general population.
Almeida, Shone   +13 more
core  

Chronic cough and esomeprazole: A double-blind placebo-controlled parallel study [PDF]

open access: yes, 2011
Background and objective: Gastro-oesophageal reflux has been implicated in the pathogenesis of chronic cough. Guidelines on management suggest a therapeutic trial of anti-reflux medication.
Beecher   +41 more
core   +1 more source

Home - About - Disclaimer - Privacy